- Home
- SLS vs SABR Comparison
SLS vs SABR Comparison
Compare SLS & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLS | SABR |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 924.5M | 842.0M |
| IPO Year | 2007 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SLS | SABR |
|---|---|---|
| Price | $12.84 | $1.85 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | $1.50 |
| AVG Volume (30 Days) | ★ 10.6M | 5.6M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.00 | ★ 283.56 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $3,866,956,000.00 |
| Revenue This Year | N/A | $7.51 |
| Revenue Next Year | $110.98 | $3.46 |
| P/E Ratio | ★ N/A | $95.50 |
| Revenue Growth | N/A | ★ 7.46 |
| 52 Week Low | $1.39 | $0.81 |
| 52 Week High | $15.88 | $3.30 |
Technical Indicators
Market Signals| Indicator | SLS | SABR |
|---|---|---|
| Relative Strength Index (RSI) | 59.89 | 47.86 |
| Support Level | $3.91 | $1.73 |
| Resistance Level | $15.88 | $1.99 |
| Average True Range (ATR) | 1.66 | 0.13 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 60.23 | 28.72 |
Price Performance
Historical ComparisonAbout SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The marketplace segment represented 80% of total 2025 revenue and airline technology solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.